SII and Oxford University’s malaria vax launched in Côte d’Ivoire
The R21/Matrix-M malaria vaccine, co-developed by the Serum Institute of India (SII) and the University of Oxford, has been launched…
The R21/Matrix-M malaria vaccine, co-developed by the Serum Institute of India (SII) and the University of Oxford, has been launched…
AusperBio has raised $37m in a Series A financing round to propel the clinical development of AHB-1 for chronic hepatitis…
Tiba Biotech, a US preclinical biopharmaceutical company based in Cambridge, Massachusetts, has announced a partnership with the Biomedical Advanced Research…
Emergent BioSolutions has received contract modifications worth more than $250m from the US Department of Health and Human Services (HHS)…
Antimicrobial resistance (AMR) is one of the biggest challenges facing healthcare systems across the globe today, with the problem expected…
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the…
Following the rapid development and commercialisation of Covid-19 vaccines and therapeutics, multiple pharmaceutical companies such as AstraZeneca, Moderna, and Pfizer…
Johnson & Johnson has received approval from the US Food and Drug Administration (FDA) approval for EDURANT PED to treat…
Merck & Co (MSD) plans to start two prospective clinical trials evaluating the safety and efficacy of a single-dose regimen…
After record-high levels of respiratory syncytial virus (RSV) were seen in several countries, the pharmaceutical landscape for RSV infections has…